102 related articles for article (PubMed ID: 10826853)
1. Prevention of coronary arterial renarrowing by continuous 3-day infusion of tissue plasminogen activator after successful percutaneous transluminal coronary angioplasty: a randomized, double-blind, placebo-controlled study.
Kanamasa K; Ogawa I; Hayashi T; Nakabayashi T; Otani N; Ishikawa K
Angiology; 2000 May; 51(5):367-75. PubMed ID: 10826853
[TBL] [Abstract][Full Text] [Related]
2. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R
Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699
[TBL] [Abstract][Full Text] [Related]
3. [Low molecular weight heparin, reviparin, after PTCA: results of a randomized double-blind, standard heparin and placebo controlled multicenter study (REDUCE Study].
Preisack MB; Baildon R; Eschenfelder V; Foley D; Garcia E; Kaltenbach M; Meisner C; Selbmann HK; Serruys PW; Shiu MF; Sujatta M; Bonan R; Karsch KR
Z Kardiol; 1997 Aug; 86(8):581-91. PubMed ID: 9417748
[TBL] [Abstract][Full Text] [Related]
4. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation.
Karsch KR; Preisack MB; Baildon R; Eschenfelder V; Foley D; Garcia EJ; Kaltenbach M; Meisner C; Selbmann HK; Serruys PW; Shiu MF; Sujatta M; Bonan R
J Am Coll Cardiol; 1996 Nov; 28(6):1437-43. PubMed ID: 8917255
[TBL] [Abstract][Full Text] [Related]
5. Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis.
Sakata K; Miura F; Sugino H; Shinobe M; Shirotani M; Yoshida H; Mori N; Hoshino T; Takada A
Am Heart J; 1996 Jan; 131(1):1-6. PubMed ID: 8553994
[TBL] [Abstract][Full Text] [Related]
6. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
Circulation; 1992 Jul; 86(1):100-10. PubMed ID: 1535568
[TBL] [Abstract][Full Text] [Related]
7. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty.
Schwartz L; Bourassa MG; Lespérance J; Aldridge HE; Kazim F; Salvatori VA; Henderson M; Bonan R; David PR
N Engl J Med; 1988 Jun; 318(26):1714-9. PubMed ID: 2967433
[TBL] [Abstract][Full Text] [Related]
8. Randomized double-blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty.
Eriksen UH; Amtorp O; Bagger JP; Emanuelsson H; Foegh M; Henningsen P; Saunamäki K; Schaeffer M; Thayssen P; Orskov H
Am Heart J; 1995 Jul; 130(1):1-8. PubMed ID: 7611096
[TBL] [Abstract][Full Text] [Related]
9. Angiographic restenosis after angioplasty: comparison of definitions and correlation with clinical outcome.
Gershlick A; Brack MJ; More RS; Syndercombe-Court D; Balcon R
Coron Artery Dis; 1993 Jan; 4(1):73-81. PubMed ID: 8269186
[TBL] [Abstract][Full Text] [Related]
10. Early decrease in minimal luminal diameter after successful percutaneous transluminal coronary angioplasty predicts late restenosis.
Rodriguez A; Santaera O; Larribeau M; Sosa MI; Palacios IF
Am J Cardiol; 1993 Jun; 71(16):1391-5. PubMed ID: 8517382
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of angiopeptin treatment in coronary angioplasty. Reduction of clinical events but not angiographic restenosis. European Angiopeptin Study Group.
Emanuelsson H; Beatt KJ; Bagger JP; Balcon R; Heikkilä J; Piessens J; Schaeffer M; Suryapranata H; Foegh M
Circulation; 1995 Mar; 91(6):1689-96. PubMed ID: 7882475
[TBL] [Abstract][Full Text] [Related]
12. Exaggerated luminal loss a few minutes after successful percutaneous transluminal coronary angioplasty in patients with recent myocardial infarction compared with stable angina: an intracoronary ultrasound study.
Lee TM; Chu CC; Hsu YM; Chen MF; Liau CS; Lee YT
Cathet Cardiovasc Diagn; 1997 May; 41(1):32-9. PubMed ID: 9143764
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of primary angioplasty with stent implantation and thrombolysis in restoring basal coronary artery flow in acute ST segment elevation myocardial infarction: quantitative assessment using the corrected TIMI frame count.
Vrachatis AD; Alpert MA; Georgulas VP; Nikas DJ; Petropoulou EN; Lazaros GI; Michelakakis NA; Karavidis AI; Lakoumentas JA; Stergiou L; Zacharoulis AA
Angiology; 2001 Mar; 52(3):161-6. PubMed ID: 11269778
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial.
Serruys PW; Klein W; Tijssen JP; Rutsch W; Heyndrickx GR; Emanuelsson H; Ball SG; Decoster O; Schroeder E; Liberman H
Circulation; 1993 Oct; 88(4 Pt 1):1588-601. PubMed ID: 8403306
[TBL] [Abstract][Full Text] [Related]
15. Association of an acute reduction in lipoprotein(a) with coronary artery restenosis after percutaneous transluminal coronary angioplasty.
Horie H; Takahashi M; Izumi M; Takaoka A; Fujita T; Sakamoto T; Kito O; Okamura H; Kinoshita M
Circulation; 1997 Jul; 96(1):166-73. PubMed ID: 9236431
[TBL] [Abstract][Full Text] [Related]
16. A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis.
Huber K; Jörg M; Probst P; Schuster E; Lang I; Kaindl F; Binder BR
Thromb Haemost; 1992 Feb; 67(2):209-13. PubMed ID: 1621240
[TBL] [Abstract][Full Text] [Related]
17. Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
Hermans WR; Rensing BJ; Foley DP; Tijssen JG; Rutsch W; Emanuelsson H; Danchin N; Wijns W; Chappuis F; Serruys PW
J Cardiovasc Pharmacol; 1993; 22 Suppl 4():S45-57. PubMed ID: 7523772
[TBL] [Abstract][Full Text] [Related]
18. Relation of coronary angioscopic findings at coronary angioplasty to angiographic restenosis.
Bauters C; Lablanche JM; McFadden EP; Hamon M; Bertrand ME
Circulation; 1995 Nov; 92(9):2473-9. PubMed ID: 7586347
[TBL] [Abstract][Full Text] [Related]
19. Effects of amlodipine on ischemia after percutaneous transluminal coronary angioplasty: secondary results of the Coronary Angioplasty Amlodipine Restenosis (CAPARES) Study.
Jørgensen B; Thaulow E;
Am Heart J; 2003 Jun; 145(6):1030-5. PubMed ID: 12796759
[TBL] [Abstract][Full Text] [Related]
20. Experience with low-dose intracoronary recombinant tissue-type plasminogen activator for nonacute total occlusions before percutaneous transluminal coronary angioplasty.
Ruocco NA; Currier JW; Jacobs AK; Ryan TJ; Faxon DP
Am J Cardiol; 1991 Dec; 68(17):1609-13. PubMed ID: 1746461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
